Unlike previous studies in MCF-7 cells, we have determined a doxorubicin-specific expression pattern in the highly tumorigenic MDA-MB-231 cell line (Zhang et al., 1991), which is p53/ER/PR-negative. In MDA-MB-231 cells, doxorubicin induced genes that regulate numerous pathways, including cellular proliferation and survival, deacidification, and membrane signaling. Using our microarray data set as candidate genes, we then inhibited three of the genes using RNAi and tested their roles in anti-neoplastic drug susceptibility. Our results support a model in which tumorigenic breast cancer cells undergo a doxorubicin-induced change in gene expression that is distinct from less malignant cells, and we have identified multiple genes that regulate anti-neoplastic drug susceptibility. For drug treatments, cells were split to a density of 500,000 cells per 100 mm dish and allowed to attach overnight. Cells were then treated with various drug concentrations and incubated for 24 hours. Cells were harvested by scraping from the dish with a rubber policeman, centrifuging, and washing once with phosphate-buffered saline. Doses of various drugs were MOL 16519 7 chosen because they cause toxicity following a prolonged incubation (data not shown).
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4 Solid tumors are typically treated with a regimen that includes DNA replication inhibitors (Chabner et al., 2001) . Because tumors replicate at a high rate, the resulting DNA damage reduces the tumor mass and suppresses spread of the tumor. However, DNA replication inhibitors generally fail to kill all of the cells within a tumor, and the surviving cells frequently develop drug resistance. One of the primary goals in cancer research is to develop new ways of inhibiting cancer cell growth, in part by improving the effectiveness of existing cancer treatment regimens. Doxorubicin (or adriamycin) is an anthracycline antibiotic that is a component of many treatment regimens for solid tumors. Doxorubicin blocks the activity of topoisomerase II, a DNA unwinding protein, causing arrest of the cell cycle or apoptosis (Chabner et al., 2001 ).
Doxorubicin resistance can emerge through altered availability of the drug or through its inactivation, through changes in topoisomerase II, or through changes in pathways mediating DNA repair and apoptosis (Longley and Johnston, 2005) . In principle, identification of genes that induced by doxorubicin could lead to new targets for improving the effectiveness of doxorubicin-based therapies.
Doxorubicin is a mainstay in the treatment of breast cancer, and several groups have used microarrays to screen for doxorubicin-regulated genes in breast cancer cell lines. Kudoh, et al. identified 14 genes that are up-regulated and 3 genes that are down-regulated by doxorubicin in MCF-7 breast cancer cells (Kudoh et al., 2000) . MCF-7 cells are a p53/estrogen receptor (ER)/progesterone receptor (PR)-positive cell line that is non-tumorigenic in the absence of estradiol (Soule and McGrath, 1980) . In general, genes that were up-regulated by doxorubicin, including cyclin D2 and Cdk6, direct cell cycle progression, while genes that were downregulated, such as Bcl-2, inhibit apoptosis. The study by Kudoh, et al., was performed with a MOL 16519 5 microarray filter containing 5180 genes, and the authors anticipated further analyses when sequencing of the human genome was complete (Kudoh et al., 2000) .
More recently, Troester, et al. analyzed global gene expression patterns in two different p53-positive breast cancer cell lines (one was the same MCF-7 cell line) treated with doxorubicin or 5-fluorouracil. These expression patterns were compared with those of mammary epithelial cells that were immortalized with telomerase (Troester et al., 2004) . For MCF-7 cells, the results of Troester, et al. differed from those of Kudoh, et al. in that genes associated with proliferation, such as CDC2, cyclin A2, Ki67, and ribonucleotide reductase, were repressed, while cell cycle inhibitors like p21 WAF1 were induced. Similar results were found more recently by Elmore, et al. (Elmore et al., 2005) . All three studies analyzed expression patterns in MCF-7 cells treated with similar doxorubicin doses (1 µM and 1.7 µM, respectively) and similar time points, and two studies detected the induction of epoxide hydrolase by doxorubicin (Kudoh et al., 2000; Troester et al., 2004) .
Other groups have used microarray-based screens to search for doxorubicin-regulated genes in hepatoma cells (Moriyama et al., 2003) , lung cancer cells (Niiya et al., 2003) , lymphoblasts (Hussain et al., 2004) , and in breast cancer cells treated with hepatocyte growth factor/scatter factor (Yuan et al., 2001) . Because these studies spanned a range of cell types and conditions, doxorubicin-regulated genes varied widely. Additional studies have used microarrays to identify expression patterns associated with doxorubicin-resistant cells. These studies identified midkine (Kang et al., 2004) and eukaryotic translation initiation factor 1A (Kang et al., 2004) , among others (Ichikawa et al., 2004; Kudoh et al., 2000) , as important in acquired doxorubicin resistance. Finally, other groups have compared doxorubicin-treated cells that display a senescent morphology with cells that have continued to proliferate. Chang, et al.
6 compared arrested and proliferating cells 10 days after a 24 hour dose of doxorubicin and identified numerous genes affecting proliferation and arrest (Chang et al., 2002) . The regulation of many of these genes was p53-dependent (Chang et al., 2002) .
Unlike previous studies in MCF-7 cells, we have determined a doxorubicin-specific expression pattern in the highly tumorigenic MDA-MB-231 cell line (Zhang et al., 1991) , which is p53/ER/PR-negative. In MDA-MB-231 cells, doxorubicin induced genes that regulate numerous pathways, including cellular proliferation and survival, deacidification, and membrane signaling. Using our microarray data set as candidate genes, we then inhibited three of the genes using RNAi and tested their roles in anti-neoplastic drug susceptibility. Our results support a model in which tumorigenic breast cancer cells undergo a doxorubicin-induced change in gene expression that is distinct from less malignant cells, and we have identified multiple genes that regulate anti-neoplastic drug susceptibility.
MATERIALS AND METHODS
Cell culture and drug treatments. The HeLa, MCF-7, and MDA-MB-231 cancer cell lines were obtained from the American Type Culture Collection (ATCC) and maintained according to their instructions. Cells were maintained in 5% CO 2 at 37 o C. Doxorubicin, camptothecin, and etoposide were purchased from Sigma. Mechlorethamine was the kind gift from the laboratory of Dr. Robert Orlowski at the University of North Carolina at Chapel Hill.
For drug treatments, cells were split to a density of 500,000 cells per 100 mm dish and allowed to attach overnight. Cells were then treated with various drug concentrations and incubated for 24 hours. Cells were harvested by scraping from the dish with a rubber policeman, centrifuging, and washing once with phosphate-buffered saline. Doses of various drugs were MOL 16519 7 chosen because they cause toxicity following a prolonged incubation (data not shown).
However, after 24 hours, none of these agents caused pronounced cellular rounding, and the FACS profiles indicated that the cells were viable and largely non-apoptotic ( Figure 1 ). The doxorubicin-regulated genes were comprised of multiple classes of genes, some of which are listed in Table I Table 1 ), but we were unable to replicate this result in independent PCR analyses (data not shown).
Doxorubicin-regulated genes are induced with varying kinetics and drug
specificities. To examine the kinetics of gene induction, we analyzed RNA levels by reverse transcription-polymerase chain reaction (RT-PCR) using actin as an internal standard for cDNA loading. CAII and Id2 were induced quickly by doxorubicin, with a detectable increase 2-6 hours after treatment ( Figure 2A and 2B). In contrast, p55PIK and Atf3 were induced more slowly, reaching peak expression only after 24 hours ( Figure 2C and 2D, respectively). These results suggest that doxorubicin-regulated genes are induced at different rates.
MOL 16519
11 Doxorubicin causes arrest of the cell cycle in the S and G 2 /M phases ( Figure 1B ). We determined whether induction of doxorubicin signature genes is cell cycle phase-specific. Like doxorubicin, the topoisomerase II inhibitor etoposide (Chabner et al., 2001) 5-fold), etoposide ( Figure 3B , lanes 6-7; 8-fold), and mechlorethamine ( Figure 3B , lanes 8-9; 10-fold). In each case, the levels of induction by doxorubicin were significantly higher than for camptothecin, etoposide, and mechlorethamine (P<0.0001 for each, Figure 3F ).
We observed similar results for p55PIK and Atf3, where doxorubicin specifically induced p55PIK ( Figure 3C and G) and Atf3 ( Figure 3D and H). In these cases, relatively low levels of induction were detected in cells treated with camptothecin, etoposide, and mechlorethamine.
The results indicate that doxorubicin induces some genes with a remarkable degree of specificity, MOL 16519 12 while other genes are induced by DNA damaging agents that do not share the cell cycle arrest profile of doxorubicin.
The CAII and clusterin proteins are induced by doxorubicin. As a consequence of its transcriptional regulation by doxorubicin, the CAII protein was induced by 1 µM doxorubicin ( Figure 4A ) and by camptothecin ( Figure 4C , lanes 2 and 3). CAII levels following treatment with etoposide or mechlorethamine were lower than levels following doxorubicin and camptothecin treatment ( Figure 4C , lanes 4 and 5), which is consistent with the RNA analysis for CAII ( Figure 3 ). Clusterin regulates chemotherapy resistance in osteosarcoma (Trougakos et al., 2004 ), and we found that clusterin was highly induced by 0.1 µM doxorubicin and was nearly saturated by a 0.5 µM dose ( Figure 4B ). In addition, clusterin was highly induced by all four chemotherapeutic agents that we tested ( Figure 4D ). We did not analyze Id2, Atf3, or p55PIK
by western blot because commercially available antibodies were not sufficiently specific. Like CAII, Id2 was expressed highly in MCF-7 cells (Fig. 5C, lane 3) , and its expression did not increase after doxorubicin treatment (Fig. 5C, lane 4) . Similar to clusterin, p55PIK was expressed at low levels in MCF-7 cells (Fig. 5D, lane 3) , and p55PIK expression decreased in MCF-7 cells after doxorubicin treatment (Fig. 5D, lane 4) . The only gene with a similar regulation in MDA-MB-231 and MCF-7 cells was Atf3, which was minimally expressed in both cell lines (Fig. 5E , lanes 1 and 3) and was induced by doxorubicin ( Fig. 5E , lanes 2 and 4).
Most of the doxorubicin-regulated genes in
CAII, Id2, Atf3, and clusterin regulate drug susceptibility. To determine the roles of doxorubicin-induced genes, we attenuated the expression of several genes using RNAi oligonucleotide duplexes (Elbashir et al., 2001) . CAII, Id2, and clusterin expression was proliferation. We will discuss these genes in the following sections.
Carbonic anhydrase II regulates the cellular acid/base balance by catalyzing the reaction:
This reaction allows for efficient secretion of acid (Potter and Harris, 2003) . Tumors have an acidic extracellular pH, which may contribute to drug resistance by reducing the uptake and cytotoxicity of weak bases like doxorubicin (Raghunand et al., 1999 Figure   5A ), suggesting that distinct pathways regulate CAII transcription in the two cell lines.
Several genes with reported anti-apoptotic functions were induced by doxorubicin in MDA-MB-231 cells. Clusterin/ Apolipoprotein J/ complement lysis inhibitor is a secreted protein that is induced by chemotherapy (Biroccio et al., 2003) . Clusterin is overexpressed in tumors (Chen et al., 2003; Redondo et al., 2000) , and has anti-apoptotic functions in some cell types (July et al., 2004; Trougakos and Gonos, 2002 ). Although we did not detect a net effect on and Id2 suppressed cell cycle progression and invasiveness (Itahana et al., 2003) . Our results using RNAi for Id2 are inconsistent with these overexpression studies, because Id2 inhibition suppressed proliferation. In some cases, constitutive overexpression of a gene phenotypically resembles the loss of the same gene, suggesting a sensitive regulation of the gene product.
Indeed, Id2 expression is transcriptionally regulated during the cell cycle (Barone et al., 1994) , and Id2 is phosphorylated by multiple kinases (Hara et al., 1997; Nagata et al., 1995) , suggesting that constitutive expression of Id2 during G 1 phase could delay cell cycle progression. (Elmore et al., 2005) , including cdc2 and cyclin E2, which are normally suppressed by doxorubicin (Elmore et al., 2005) . In contrast, Id2 (a gene associated with proliferation) caused decreased survival in MDA-MB-231 cells, the opposite result. We conclude that MCF-7 cells suppress chemotherapy susceptibility through a distinct mechanism from MDA-MB-231 cells.
Phosphatidylinositol 3-kinase (PI3K) has anti-apoptotic functions in response to numerous stimuli (Fresno Vara et al., 2004) , and we detected marked up-regulation of the PI3K regulatory sub-unit p55PIK/PI3K-p55γ (Pons et al., 1995) by doxorubicin. While the role of p55PIK in growth regulation is poorly understood, p55PIK binds to the Rb tumor suppressor protein (Xia et al., 2003) , and overexpression of the amino-terminal Rb binding sequence of p55PIK causes growth arrest (Hu et al., 2005) . p55PIK is also implicated in insulin and cytokine signaling (Dey et al., 1998; Mothe et al., 1997; Takahashi-Tezuka et al., 1997) . In addition, we note that p55PIK was not induced by doxorubicin in MCF-7 cells, suggesting genetic factors that are altered in MDA-MB-231 cells regulate p55PIK expression.
Several other genes that are associated with proliferation were induced by doxorubicin.
Atf3 is a member of the ATF/CREB (activating transcription factor/cAMP responsive element binding protein) family of bZip transcription factors (Hai and Hartman, 2001) . Atf3 binds to the DNA sequence TGACGTCA and is associated with neoplastic transformation and the response to serum, stress, and damage (Amundson et al., 1999; Hai and Hartman, 2001; Shtil et al., 1999; Yu et al., 1996) . Atf3 was up-regulated by doxorubicin in MDA-MB-231 and MCF-7 cells, suggesting that strategies targeting Atf3 would be unlikely to be specific for aggressive cancers.
Other pro-survival genes that were induced by doxorubicin include TRAIL-R3 and TRAIL-R4, which are "decoy receptors" for TRAIL, the tumor necrosis factor-related apoptosis MOL 16519
19 inducing ligand (Kim and Seol, 2003) . TRAIL-R3 and TRAIL-R4 bind to TRAIL but lack cytoplasmic death domains and do not induce apoptosis when engaged by TRAIL (Sheridan et al., 1997) . Instead, TRAIL-R3 and TRAIL-R4 have anti-apoptotic functions (Bernard et al., 2001; Meng et al., 2000) . TRAIL-R3 has been reported previously as a doxorubicin-responsive gene in breast cancer (Ruiz de Almodovar et al., 2004) , and our findings also implicate TRAIL-R4 in resistance to doxorubicin-mediated cell death. In addition, numerous genes that modulate cell death were down-regulated by doxorubicin, including multiple interleukins. Among these genes, IL-1α has been investigated previously for its ability to enhance the anti-cancer activity of doxorubicin (Monti et al., 1993; Nakamura et al., 1991) .
Doxorubicin also induced the expression of proteins that metabolize xenobiotic compounds, including the cytochrome P450 proteins Cyp1A1 and Cyp1B1, the cytochrome P450 reductase, and the cytochrome b 5 -related P450 activator Iza1/Hpr6.6 (Table 1 ). Cyp1A1
and Cyp1B1 are induced in response to numerous aromatic compounds with similar structures to doxorubicin (Nebert and Russell, 2002) . Iza1 homologues activate and stabilize cytochrome P450 proteins (Mallory et al., 2005; Min et al., 2004) , and Iza1 regulates cell death following oxidative damage (Hand and Craven, 2003) , which is generated by doxorubicin. As a group, these proteins likely modify doxorubicin or cellular metabolites induced by doxorubicin.
Cytochrome P450 proteins likely act in concert with the drug transporter proteins GCN20/ABCF2 and MDRTAP, which were induced by doxorubicin (Table 1) , in minimizing the effective concentrations of doxorubicin within the cell.
In summary, we have identified a group of genes that are induced by chemotherapeutic agents and which regulate drug susceptibility. The functions of individual genes could not be predicted based on their transcriptional pattern, because genes that were induced by doxorubicin Each of the four genes was induced most highly by doxorubicin, and the ratio of each gene to actin in doxorubicin-treated cells is expressed as 100%. Error bars represent the standard deviation in three independent assays. The results showed that CAII is induced by multiple drugs, while Id2, Atf3, and p55PIK were induced primarily by doxorubicin. and increased in both cell lines upon doxorubicin treatment (lanes 2 and 4). The results show that the various RNAi duplexes inhibit doxorubicin-induced gene expression. 
